Baxter International today announced that Vantive will be the name of the company’s proposed spinoff of its Renal Care and Acute Therapies businesses. Vantive is expected to launch as an independent, publicly traded company by July 2024 or earlier, subject to satisfaction of customary conditions.
Vantive will carry forward Baxter’s nearly 70-year legacy of specializing in kidney disease and organ support therapies. The company will continue to serve as a partner to providers and clinicians around the world, focusing on improving outcomes for the more than one million patients it serves annually in more than 70 countries. Vantive will continue its focus on driving change in kidney care and organ support through technologies, digital connectivity, and services to better support clinicians and patients. As a standalone entity with its own investment priorities and enhanced management focus, Vantive should be better positioned to pursue growth opportunities and invest in innovation.
The Vantive logo and full visual identity will be unveiled at a later date. Until completion of the proposed separation in 2024, the Kidney Care business will continue to operate as Baxter. Read more about the proposed Kidney Care spinoff here.
